The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CRBP | +1.6% | -41.45% | -10.15% | -80% |
| S&P | +14.5% | +93.32% | +14.09% | +242% |
Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, which focuses on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its products include candidate, Lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. The company was founded in April 2009 and is headquartered in Norwood, MA.
You might want to avoid buying it, though.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.10M | 50.0% |
| Market Cap | $84.43M | -82.5% |
| Market Cap / Employee | $3.02M | 0.0% |
| Employees | 28 | 47.4% |
| Net Income | -$17.66M | -76.7% |
| EBITDA | -$19.05M | -76.6% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $20.33M | -15.2% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.76M | -69.0% |
| Short Term Debt | $1.70M | -86.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -41.83% | -6.1% |
| Return On Invested Capital | 180.28% | 94.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$16.60M | -85.6% |
| Operating Free Cash Flow | -$16.60M | -85.6% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.89 | 0.95 | 0.45 | 0.66 | -86.46% |
| Price to Tangible Book Value | 1.89 | 0.95 | 0.45 | 0.66 | -86.46% |
| Enterprise Value to EBITDA | -6.00 | 0.19 | 3.33 | 1.57 | -104.61% |
| Return on Equity | -51.3% | -59.3% | -44.9% | -49.0% | -5.37% |
| Total Debt | $3.61M | $3.24M | $2.86M | $2.46M | -83.40% |
CRBP earnings call for the period ending December 31, 2020.
CRBP earnings call for the period ending September 30, 2020.
CRBP earnings call for the period ending June 30, 2020.
CRBP earnings call for the period ending March 31, 2020.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
